Clozapine vs Risperidone (Risperdal)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline
Clozapine
Marketed by HLS Therapeutics Inc.
NCT00250575 · Phase 3 · completed
The study was open-label, single-arm, and had no placebo or active comparator; all 43 participants received clozapine. Its primary measures focused on hematological tests, blood-related adverse events, and monitoring-system compliance rather than a clinical symptom endpoint, and no results are posted.
Next expected readout: April 2027 · NCT04580134 (registry estimate)
Reported efficacy
Treatment efficacy rate (baseline,0.5 months,1 months, 2 months,4 months , 6 months , 8 months and 12 months); All-cause dropout rate (baseline,0.5 months,1 months, 2 months,4 months , 6 months , 8 months and 12 months): Primary 1, symptomatic response (40% or more PANSS total reduction) in phase 2 among 111 re-randomized nonresponders: clozapine 62.5% (20/32) vs amisulpride 44.7% (17/38) vs olanzapine 31.7% (13/41) (chi-square 6.9; P=.03), met. Primary 2, time to all-cause discontinuation: the paper reports no clear difference between treatment groups, missed. (mixed)
Result source: NCT03510325
Risperidone (Risperdal)
Marketed by Johnson & Johnson
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: September 2027 · NCT04478838 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Schizophrenia
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
These assets measured different things. Their trials share no endpoint in common, so no efficacy row can be built. That is a property of the programmes rather than a gap in the record: each asset's own reported endpoints are listed below.
| Key endpoint | Clozapine | Risperidone (Risperdal) |
|---|---|---|
| PANSS total, change | —Not posted · NCT00649844 | -16.5 vs -9.2−7.2 vs placeboNCT021095621 other result
|
| CGI-S, change | —Not posted · NCT00649844 | -0.9 vs -0.5−0.4 vs placeboNCT021095621 other result
|
| PANSS response | —Not posted · NCT00649844 | —Not posted · NCT00297388 |
| PSP, change | —Not posted · NCT00649844 | —Not posted · NCT00297388 |
| Relapse (% of patients) | —Not posted · NCT00649844 | —Not posted · NCT00297388 |
PANSS total, change
- Clozapine
- —Not posted · NCT00649844
- Risperidone (Risperdal)
- -16.5 vs -9.2−7.2 vs placeboNCT02109562
1 other result
- -15.4 vs -9.2 NCT02109562
CGI-S, change
- Clozapine
- —Not posted · NCT00649844
- Risperidone (Risperdal)
- -0.9 vs -0.5−0.4 vs placeboNCT02109562
1 other result
- -0.9 vs -0.5 NCT02109562
PANSS response
- Clozapine
- —Not posted · NCT00649844
- Risperidone (Risperdal)
- —Not posted · NCT00297388
PSP, change
- Clozapine
- —Not posted · NCT00649844
- Risperidone (Risperdal)
- —Not posted · NCT00297388
Relapse (% of patients)
- Clozapine
- —Not posted · NCT00649844
- Risperidone (Risperdal)
- —Not posted · NCT00297388
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Clozapine: 3 of 4 rows · Risperidone (Risperdal): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Clozapine | Risperidone (Risperdal) |
|---|---|---|
| Dropout rate | 41.7%a NCT01639872 · Phase 4 · registry result, not featured evidence show 2 more results0% NCT00498550 · Phase 4 · registry result, not featured evidence 17.2% NCT02404155 · Phase na · registry result, not featured evidence | 78.3%180 mg subcutaneousa NCT03978832 · Phase 4 · registry result, not featured evidence show 22 more results5.9%CT - Oral Ris NCT00333177 · Phase 4 · registry result, not featured evidence 0%CT - RLAI NCT00333177 · Phase 4 · registry result, not featured evidence 14.3%HBT - Oral Ris NCT00333177 · Phase 4 · registry result, not featured evidence 5.9%HBT - RLAI NCT00333177 · Phase 4 · registry result, not featured evidence 0% NCT01050582 · Phase 4 · registry result, not featured evidence 17.5% NCT01855074 · Phase 4 · registry result, not featured evidence 29.6% NCT00299702 · Phase 4 · registry result, not featured evidence 0%PALI ER Delayed Initiation NCT00535132 · Phase 4 · registry result, not featured evidence 0%PALI ER Immediate Initiation NCT00535132 · Phase 4 · registry result, not featured evidence 16.7% NCT00056498 · Phase 4 · registry result, not featured evidence 28.6%120 mg NCT02109562 · Phase 3 · registry result, not featured evidence 22.4%90 mg NCT02109562 · Phase 3 · registry result, not featured evidence —4 mg NCT04567524 · Phase 2 · registry result, not featured evidence 25%4 mg NCT04567524 · Phase 2 · registry result, not featured evidence —2 mg NCT04567524 · Phase 2 · registry result, not featured evidence 0%2 mg NCT04567524 · Phase 2 · registry result, not featured evidence 40%120 mg NCT01677377 · Phase 2 · registry result, not featured evidence 6.7%90 mg NCT01677377 · Phase 2 · registry result, not featured evidence 6.7%60 mg NCT01677377 · Phase 2 · registry result, not featured evidence 29.4%DLP-114 Alpha-4 (6-months) NCT04418466 · Phase 1/2 · registry result, not featured evidence 35.3%DLP-114 Alpha-7 (12-months) NCT04418466 · Phase 1/2 · registry result, not featured evidence 44% NCT01786239 · Phase na · registry result, not featured evidence |
| Discontinued due to AEs | —a NCT01639872 · Phase 4 · registry result, not featured evidence show 2 more results— NCT00498550 · Phase 4 · registry result, not featured evidence — NCT02404155 · Phase na · registry result, not featured evidence | 1.4%180 mg subcutaneousa NCT03978832 · Phase 4 · registry result, not featured evidence show 22 more results—CT - Oral Ris NCT00333177 · Phase 4 · registry result, not featured evidence —CT - RLAI NCT00333177 · Phase 4 · registry result, not featured evidence —HBT - Oral Ris NCT00333177 · Phase 4 · registry result, not featured evidence —HBT - RLAI NCT00333177 · Phase 4 · registry result, not featured evidence — NCT01050582 · Phase 4 · registry result, not featured evidence 1.3% NCT01855074 · Phase 4 · registry result, not featured evidence 0% NCT00299702 · Phase 4 · registry result, not featured evidence —PALI ER Delayed Initiation NCT00535132 · Phase 4 · registry result, not featured evidence —PALI ER Immediate Initiation NCT00535132 · Phase 4 · registry result, not featured evidence — NCT00056498 · Phase 4 · registry result, not featured evidence 1.7%120 mg NCT02109562 · Phase 3 · registry result, not featured evidence 0%90 mg NCT02109562 · Phase 3 · registry result, not featured evidence —4 mg NCT04567524 · Phase 2 · registry result, not featured evidence 0%4 mg NCT04567524 · Phase 2 · registry result, not featured evidence —2 mg NCT04567524 · Phase 2 · registry result, not featured evidence 0%2 mg NCT04567524 · Phase 2 · registry result, not featured evidence —120 mg NCT01677377 · Phase 2 · registry result, not featured evidence —90 mg NCT01677377 · Phase 2 · registry result, not featured evidence —60 mg NCT01677377 · Phase 2 · registry result, not featured evidence —DLP-114 Alpha-4 (6-months) NCT04418466 · Phase 1/2 · registry result, not featured evidence —DLP-114 Alpha-7 (12-months) NCT04418466 · Phase 1/2 · registry result, not featured evidence — NCT01786239 · Phase na · registry result, not featured evidence |
| Serious AEs | 13%a NCT01639872 · Phase 4 · registry result, not featured evidence show 2 more results26.7% NCT00498550 · Phase 4 · registry result, not featured evidence 6.9% NCT02404155 · Phase na · registry result, not featured evidence | 4.3%180 mg subcutaneousa NCT03978832 · Phase 4 · registry result, not featured evidence show 22 more results18.8%CT - Oral Ris NCT00333177 · Phase 4 · registry result, not featured evidence 8.3%CT - RLAI NCT00333177 · Phase 4 · registry result, not featured evidence 8.3%HBT - Oral Ris NCT00333177 · Phase 4 · registry result, not featured evidence 0%HBT - RLAI NCT00333177 · Phase 4 · registry result, not featured evidence 0% NCT01050582 · Phase 4 · registry result, not featured evidence 1.3% NCT01855074 · Phase 4 · registry result, not featured evidence 17.3% NCT00299702 · Phase 4 · registry result, not featured evidence 4%PALI ER Delayed Initiation NCT00535132 · Phase 4 · registry result, not featured evidence 3.1%PALI ER Immediate Initiation NCT00535132 · Phase 4 · registry result, not featured evidence 3.3% NCT00056498 · Phase 4 · registry result, not featured evidence 0.9%120 mg NCT02109562 · Phase 3 · registry result, not featured evidence 0%90 mg NCT02109562 · Phase 3 · registry result, not featured evidence 0%4 mg NCT04567524 · Phase 2 · registry result, not featured evidence —4 mg NCT04567524 · Phase 2 · registry result, not featured evidence 0%2 mg NCT04567524 · Phase 2 · registry result, not featured evidence —2 mg NCT04567524 · Phase 2 · registry result, not featured evidence 6.7%120 mg NCT01677377 · Phase 2 · registry result, not featured evidence 0%90 mg NCT01677377 · Phase 2 · registry result, not featured evidence 0%60 mg NCT01677377 · Phase 2 · registry result, not featured evidence 0%DLP-114 Alpha-4 (6-months) NCT04418466 · Phase 1/2 · registry result, not featured evidence 7.1%DLP-114 Alpha-7 (12-months) NCT04418466 · Phase 1/2 · registry result, not featured evidence 0% NCT01786239 · Phase na · registry result, not featured evidence |
| Most frequent reported AEs | a other-sialorrhea 43.5% weight gain 30.4% sedation 21.7% NCT01639872 · Phase 4 · registry result, not featured evidence show 2 more resultsgastrointestinal disorder - other: hypersalivation 66.7% somnolence 60% weight gain 40% NCT00498550 · Phase 4 · registry result, not featured evidence salivation 68.2% sedation 52.9% malaise 52.6% NCT02404155 · Phase na · registry result, not featured evidence | 180 mg subcutaneousa upper respiratory tract infection 13% blood prolactin increased 8.7% decreased appetite 8.7% NCT03978832 · Phase 4 · registry result, not featured evidence show 18 more resultsbmi increase normal/overweight to obese 31.3% ldl or triglyceride increase 25% prolactin related symptom 12.5% NCT00333177 · Phase 4 · registry result, not featured evidence bmi increase normal/overweight to obese 25% prolactin related symptom 16.7% ldl or triglyceride increase 8.3% NCT00333177 · Phase 4 · registry result, not featured evidence ldl or triglyceride increase 41.7% prolactin related symptom 16.7% bmi increase normal/overweight to obese 0% NCT00333177 · Phase 4 · registry result, not featured evidence bmi increase normal/overweight to obese 12.5% ldl or triglyceride increase 6.3% prolactin related symptom 6.3% NCT00333177 · Phase 4 · registry result, not featured evidence blood prolactin increased 0.8% drug ineffective 0.8% eye infection 0.8% NCT01050582 · Phase 4 · registry result, not featured evidence extrapyramidal disorder 1.3% NCT01855074 · Phase 4 · registry result, not featured evidence insomnia 26.3% tremor 21.8% anxiety 17.9% NCT00299702 · Phase 4 · registry result, not featured evidence constipation 9.1% insomnia 9.1% somnolence 8.1% NCT00535132 · Phase 4 · registry result, not featured evidence insomnia 9.2% headache 8.2% constipation 6.1% NCT00535132 · Phase 4 · registry result, not featured evidence 120 mg injection site pain 22.2% (placebo 19.5%) headache 15.4% (placebo 23.7%) weight increased 12.8% (placebo 3.4%) NCT02109562 · Phase 3 · registry result, not featured evidence 90 mg headache 17.4% (placebo 23.7%) injection site pain 15.7% (placebo 19.5%) weight increased 13% (placebo 3.4%) NCT02109562 · Phase 3 · registry result, not featured evidence 4 mg akathisia 25% diarrhoea 25% abdominal discomfort 0% NCT04567524 · Phase 2 · registry result, not featured evidence 2 mg alanine aminotransferase increased 25% weight increased 25% abdominal discomfort 0% NCT04567524 · Phase 2 · registry result, not featured evidence 120 mg cough 20% dyspepsia 20% weight increased 20% NCT01677377 · Phase 2 · registry result, not featured evidence 90 mg weight increased 33.3% headache 20% dyspepsia 13.3% NCT01677377 · Phase 2 · registry result, not featured evidence 60 mg weight increased 26.7% headache 20% rash 20% NCT01677377 · Phase 2 · registry result, not featured evidence arthralgia 21.4% weight increased 21.4% abdominal pain 14.3% NCT04418466 · Phase 1/2 · registry result, not featured evidence insomnia 21.4% implant site pain 14.3% injection site discomfort 14.3% NCT04418466 · Phase 1/2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Clozapine
Risperidone (Risperdal)
+ 24 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Clozapine's landscape · Risperidone (Risperdal)'s landscape